Sol-Gel Completes Phase 3 Trial of Patidegib Gel 2% for Facial Basal Cell Carcinomas in Gorlin Syndrome
核心洞察
Sol-Gel Technologies has completed its Phase 3 study of patidegib gel 2% (搜索) (SGT-610) in adults with Gorlin syndrome (搜索), a condition marked by repeated facial skin cancers.
The multicenter, randomized, double-blind, vehicle-controlled trial evaluated whether twice-daily topical patidegib can reduce the number of new basal cell carcinomas on the face.
The study was submitted on September 15, 2023 and updated on September 17, 2026, indicating data collection is finished and full analysis is under way.
Sol-Gel Technologies, Ltd. has completed its Phase 3 clinical study of patidegib gel 2% (搜索), also known as SGT-610, in adults with Gorlin syndrome (搜索), a condition that causes repeated skin cancers on the face. The trial is recorded as completed and was recently updated, with data collection now finished and the sponsor moving toward full analysis and eventual disclosure of results.
Trial Design and Endpoints
The study is a multicenter, randomized, double-blind, vehicle-controlled Phase 3 trial. Participants were randomly assigned to receive either patidegib gel 2% (搜索) or a placebo gel, with neither the participants nor their physicians knowing which treatment was administered.
The primary objective is preventive rather than therapeutic: the trial was designed to determine whether the gel can reduce the number of new basal cell carcinomas and do so safely. The treatment is applied topically to the face twice daily, a regimen intended to fit into patients' daily routines.
The trial was submitted on September 15, 2023, and set up a year of treatment and follow-up to count new facial cancers. The most recent update was submitted on September 17, 2026, signaling that data collection is complete.
Clinical Rationale in a High-Need Niche
Gorlin syndrome (搜索) is described as a rare but high-need condition in which patients develop repeated skin cancers on the face. The preventive approach under study targets the formation of new facial tumors in this high-risk group rather than treating existing lesions.
What Comes Next
Headline efficacy and safety numbers are not yet public. Completion of the Phase 3 program reduces development risk for the asset and could support future regulatory filings and partnership discussions. Sol-Gel now holds a completed late-stage program in dermatology, a differentiated position in skin cancer prevention, though competition in that space and larger oncology pipelines from bigger players may temper expectations. Further details are available on the ClinicalTrials portal.